|
The gore® cardioform septal occluder instructions for use warns; adverse events associated with the use of the occluder may include, but are not limited to: - significant pleural or pericardial effusion requiring drainage w.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
It was reported to gore that a gore® cardioform septal occluder was selected to treat an adult patient with a patent foramen ovale (pfo).The device was successfully implanted.However, while preparing to transfer the patient to recovery, the patient experienced a sudden drop in blood pressure.The groin access site was assessed and found to be intact.Further evaluation revealed fluid accumulation in the pericardium, suggesting a possible perforation.Approximately 800 ml to 1 liter of pericardial fluid was drained in the cath lab, stabilizing the patient for safe transport.The patient required transfusion and was taken to surgery, where the defect was patched.The occluder device remains implanted, and the patient is currently stable.
|